Jingbo Yu1, Shreekant Parasuraman1, Anshul Shah2, Daniel Weisdorf3. 1. a Incyte Corporation, US Medical Affairs , Wilmington , DE , USA. 2. b Evidera Inc. , Modeling and Simulation , Waltham , MA , USA. 3. c University of Minnesota , Department of Medicine, Division of Hematology, Oncology and Transplantation , Minneapolis , MN , USA.
Abstract
OBJECTIVE: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. METHODS: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. RESULTS: Overall, mortality (16.2% vs. 5.3%; p < .01), median hospital LOS (42.0 vs. 26.0 days; p < .01) and median total costs ($173,144 vs. $98,982; p < .01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. CONCLUSION: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.
OBJECTIVE: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. METHODS: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. RESULTS: Overall, mortality (16.2% vs. 5.3%; p < .01), median hospital LOS (42.0 vs. 26.0 days; p < .01) and median total costs ($173,144 vs. $98,982; p < .01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. CONCLUSION: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.
Authors: Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio Journal: Blood Adv Date: 2020-04-28
Authors: Leonardo Javier Arcuri; Cinthya Corrêa da Silva; Lidiane Soares Sodre da Costa; Mirele Vanesca Ferreira Dos Santos; Ancelmo Honorato Ferraz de Sousa; Cristina Vogel; Angelo Maeda Rojas; Helena Lumi Fukumoto; Marci Pietrocola; Paula Oliveira de Souza; Silvia Regina Morgado; Tânia Michele Barreto Waisbeck; Nelson Hamerschlak Journal: Ann Hematol Date: 2022-09-12 Impact factor: 4.030
Authors: Lorenzo Sabatelli; Mikko Keränen; Elisabet Viayna; Montserrat Roset; Nuria Lara; Daniel Thunström; Minja Pfeiffer; Malin Nicklasson; Maija Itälä-Remes Journal: Support Care Cancer Date: 2022-03-02 Impact factor: 3.603
Authors: Nikolett Lupsa; Ákos Szegedi; András Gézsi; Zoltán Vuncs; Tamás Masszi; Gábor Mikala; Péter Reményi; Sara Deola; Arun Prasath Lakshmanan; Annalisa Terranegra; Edit I Buzás; Zoltán Pós Journal: Biomedicines Date: 2022-02-22